drugset / Trial / NCT00352911
Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
The objective of the study is to determine whether mifepristone (VGX-410) has anti-HIV-1 activity at doses of either 300 mg or 600 mg per day after oral administration for 14 days at each dose level.
Timeline
- Start
- 2006-07
- Primary completion
- 2007-06
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mifepristone | Small molecule | 150 mg | Oral |
| Comparator | Mifepristone | Small molecule | 300 mg | Oral |